Arcellx Inc (ACLX)
NASDAQ:ACLX
Want to see ACLX full AI Analyst Report?
Top Page
Arcellx Inc
(NASDAQ:ACLX)
Select Model
Select Model
Rating:58Neutral
Price Target:
$120.00
▲(4.30% Upside)
Action:ReiteratedDate:04/29/26
The score is held back primarily by weak financial performance (no reported 2025 revenue, widening losses, and accelerating cash burn) and loss-based valuation (negative P/E). These are partially offset by strong corporate-event support from the completed take-private acquisition with defined cash consideration plus CVR upside, and by a technically strong trend that is tempered by overbought momentum readings.
Positive Factors
Regulatory Progress (BLA)
FDA acceptance of anito-cel's BLA with a set PDUFA date materially raises the probability of approval. Over the next 2–6 months this reduces binary regulatory risk, strengthens commercialization visibility for the program and supports long-term revenue potential if approved.
Negative Factors
Accelerating Cash Burn
Accelerating cash burn and deeply negative free cash flow materially increase funding risk and constrain operational flexibility. Over a 2–6 month horizon this reduces runway for independent development, forces reliance on external capital or acquirer support, and limits discretionary spending.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory Progress (BLA)
FDA acceptance of anito-cel's BLA with a set PDUFA date materially raises the probability of approval. Over the next 2–6 months this reduces binary regulatory risk, strengthens commercialization visibility for the program and supports long-term revenue potential if approved.
Read all positive factors
Arcellx Inc (ACLX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$6.73B
Dividend YieldN/A
Average Volume (3M)1.12M
Price to Earnings (P/E)―
Beta (1Y)0.66
Revenue Growth-79.35%
EPS Growth-103.50%
CountryUS
Employees163
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.00
Shares Outstanding58,506,348
10 Day Avg. Volume599,825
30 Day Avg. Volume1,119,312
Financial Highlights & Ratios
PEG Ratio-0.15
Price to Book (P/B)9.12
Price to Sales (P/S)164.73
P/FCF Ratio-17.27
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue302.62
Enterprise Value/Gross Profit-466.95
Enterprise Value/Ebitda-34.07
Forecast
1Y Price Target
$112.67Price Target Upside-2.07% Downside
Rating ConsensusHold
Number of Analyst Covering15
EPS Forecast (FY)-3.54
Revenue Forecast (FY)$74.28M
Arcellx Inc Business Overview & Revenue Model
Company Description
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clin...
How the Company Makes Money
Arcellx primarily makes money through (1) collaboration and licensing arrangements with larger pharmaceutical partners, which can include upfront payments, research and development funding or cost reimbursement, and milestone payments tied to deve...
Arcellx Inc Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
58
Neutral
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 22.29M | 107.94M | 110.32M | 0.00 | 0.00 |
| Gross Profit | 15.61M | 102.75M | 110.32M | -2.22M | 0.00 |
| EBITDA | -197.97M | -99.06M | -64.14M | -184.74M | -63.92M |
| Net Income | -228.93M | -107.35M | -70.69M | -188.68M | -64.97M |
Balance Sheet | |||||
| Total Assets | 603.99M | 711.33M | 825.13M | 313.82M | 128.78M |
| Cash, Cash Equivalents and Short-Term Investments | 450.33M | 587.58M | 702.02M | 254.84M | 104.62M |
| Total Debt | 96.26M | 54.08M | 97.63M | 88.13M | 0.00 |
| Total Liabilities | 201.64M | 256.54M | 339.75M | 108.86M | 250.30M |
| Stockholders Equity | 402.35M | 454.79M | 485.38M | 204.95M | -121.52M |
Cash Flow | |||||
| Free Cash Flow | -212.59M | -96.90M | 186.15M | -101.58M | -60.02M |
| Operating Cash Flow | -210.26M | -83.47M | 207.57M | -99.30M | -54.24M |
| Investing Cash Flow | 86.30M | -183.04M | -154.51M | -117.67M | -79.98M |
| Financing Cash Flow | 98.53M | -24.09M | 279.16M | 252.63M | 118.45M |
Arcellx Inc Technical Analysis
Positive
115.05
Price Trends
104.27
Positive
86.42
Positive
82.05
Positive
Market Momentum
2.38
Positive
80.91
Negative
83.65
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ACLX, the sentiment is Positive. The current price of 115.05 is above the 20-day moving average (MA) of 114.79, above the 50-day MA of 104.27, and above the 200-day MA of 82.05, indicating a bullish trend. The MACD of 2.38 indicates Positive momentum. The RSI at 80.91 is Negative, neither overbought nor oversold. The STOCH value of 83.65 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ACLX.
Arcellx Inc Risk Analysis
Arcellx Inc disclosed 88 risk factors in its most recent earnings report. Arcellx Inc reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Arcellx Inc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $6.29B | -31.28 | -19.89% | ― | -89.41% | -145.57% | |
62 Neutral | $5.83B | -10.43 | -65.80% | ― | ― | -2.53% | |
58 Neutral | $6.73B | -16.04 | -55.42% | ― | -79.35% | -103.50% | |
58 Neutral | $3.00B | -34.27 | -7.31% | ― | 120.01% | 78.83% | |
56 Neutral | $5.23B | 141.40 | 8.20% | ― | 28.46% | ― | |
54 Neutral | $1.21B | -3.74 | -67.12% | ― | ― | -86.55% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
ACLX
Arcellx Inc
115.07
50.12
77.17%
PTGX
Protagonist Therapeutics
101.21
55.39
120.89%
APLS
Apellis Pharmaceuticals
40.99
21.78
113.38%
IMVT
Immunovant
26.99
10.84
67.12%
BEAM
Beam Therapeutics
30.56
10.63
53.34%
MLTX
MoonLake Immunotherapeutics
16.66
-25.42
-60.41%
Arcellx Inc Corporate Events
Business Operations and StrategyExecutive/Board ChangesDelistings and Listing ChangesM&A TransactionsRegulatory Filings and Compliance
Arcellx Acquired in Cash-and-CVR Deal, Going Private
Positive
Apr 28, 2026
On March 6, 2026, a purchaser launched a tender offer to acquire all outstanding shares of Arcellx Inc. common stock at $115 in cash plus a contingent value right (CVR) worth up to $5 per share, tied to cumulative worldwide sales of the company...
Business Operations and StrategyM&A TransactionsProduct-Related AnnouncementsRegulatory Filings and Compliance
Arcellx Advances Anito-cel as FDA Accepts BLA Filing
Positive
Feb 23, 2026
On February 22, 2026, Arcellx entered into a definitive merger agreement under which Gilead Sciences will acquire the company via a tender offer and follow-on merger for $115 in cash per share plus a $5 contingent value right, implying equity valu...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.